Immunovant’s IMVT Bets on IMVT-1402 as Batoclimab Exits Stage Left: A Q4/Q1 2026 Update

Ticker: IMVT | Date: May 20, 2026 | The company reports fourth quarter and fiscal year results for the year ended March 31, 2026. EPS, EPS consensus, revenue forecast, and earnings surprise are in focus as investors parse the news.

Immunovant, Inc., trading as IMVT on Nasdaq, tees up a story about pivot and runway rather than a single product victory lap. The press release covers corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2026, with a clear emphasis on IMVT-1402’s early signal in difficult-to-treat rheumatoid arthritis (D2T RA), an enjoined look at the fully enrolled proof-of-concept for cutaneous lupus erythematosus (CLE), and a strategic retreat from batoclimab after April 2026 data. The company reiterates a cash runway that could support a potential IMVT-1402 launch in Graves’ disease, MG, CIDP, and Sjögren’s disease—procedurally neat, operationally messy in the clinical detail, and financially noncommittal enough to keep both bears and bulls honest for another quarter.

Clinical progress: IMVT-1402 in RA and CLE poised for follow-on data

The Week 16 results from IMVT-1402 in D2T RA show ACR20 at 72.7%, ACR50 at 54.5%, and ACR70 at 35.8% during the open-label Period 1.
170 participants have been enrolled in Period 1; randomization into Period 2 will compare IMVT-1402 600 mg, 300 mg, and placebo for 12 weeks, with the primary endpoint at Week 28.
The CLE trial is fully enrolled, with topline data anticipated in the second half of calendar year 2026.
Management frames IMVT-1402 as potentially registrational in Graves’ disease, MG, CIDP, and Sjögren’s disease, contingent on continued favorable data and regulatory signals.

Financials and forward-looking metrics

The filing emphasizes a cash balance and operational runway but does not disclose exact EPS, EPS consensus, revenue figures, or formal earnings surprises in the excerpt. Investors will be watching for a more complete set of metrics in forthcoming filings and the May 20 conference call, with particular attention to EPS and a revenue forecast that align with the autoimmune-therapy narrative. In other words, the headline numbers will matter less than whether the trajectory supports additional dilution-free upside and a path to potential commercialization of IMVT-1402.

Strategic pivots: Batoclimab exit and a sharpened IMVT-1402 focus

The April 2026 topline results from batoclimab in thyroid eye disease did not meet primary endpoints, prompting Immunovant to discontinue the program across all indications. The company notes that learnings from batoclimab—operational, clinical, and investigator relationships—will be leveraged to inform IMVT-1402 development. It’s a reroute, not a retreat: capital discipline paired with a more defensible, dose-focused Phase 2/3 pathway for IMVT-1402 could improve the odds of a meaningful clinical and regulatory payoff if Week 16 signals hold up.

Upcoming catalysts and investor interactions

Roivant will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to discuss the updates. The schedule matters: topline data from IMVT-1402 in RA are anticipated in 2026’s second half, with potential registrational studies in GD and MG on the horizon if the program continues to show robust efficacy and an acceptable safety profile. In a sector where a single clean signal can reprice a stock, the next few quarters look consequential for IMVT’s narrative and for peers pursuing similar autoimmune targets.

Market implications for Immunovant and sector peers

The Immunovant update illustrates a common biotech crosswind: keep the narrative credible by presenting progress on multiples while managing the capital framework. If IMVT-1402 sustains Week 16 efficacy in RA and demonstrates a favorable safety profile, the stock could rerate on the basis of a viable, near-term path to registrational trials in other autoimmune indications. For sector peers, the emphasis on subcutaneous weekly dosing and open-label lead-ins offers a blueprint for managing trial design risk and patient retention, especially in diseases where long-term adherence is critical. Conversely, any erosion of Week 16 efficacy signals or setbacks in CLE topline data could compress the risk premium across the autoimmune space and boost the weight of earlier-stage programs that deliver quicker readouts.

Conclusion: a measured pivot with optionality

Immunovant’s release does not scream “EPS blockbuster” or “revenue forecast beat” in the near term; it signals a strategic launchpad where the strength of IMVT-1402’s signal could unlock a longer runway for GL, MG, and related indications. The company’s choice to retire batoclimab while doubling down on a potentially registrational pathway reflects a disciplined approach to capital allocation—one that acknowledges clinical uncertainty while preserving optionality. For investors, the headline is less about a single earnings surprise and more about whether the forthcoming data cadence can validate a multi-asset autoimmune thesis for IMVT and its peers. Ticker IMVT remains the focal point, with EPS iterative updates and revenue forecasts likely to follow a data-driven glow in the months ahead.